Submit Manuscript  

Article Details

Regulatory T Cell Therapy for Type I Diabetes Targeting on β Cell Associated Autoantigens

[ Vol. 3 , Issue. 1 ]


Suidong Ouyang and Ji-Ming Feng   Pages 47 - 53 ( 7 )


Type I diabetes (T1D) is an organ-specific autoimmune disease that targets on the destruction of insulin-producing pancreatic β cells. Many strategies, including immunosuppressive and antigen-specific immunoregulatory therapies, have been per- formed in animal models and in the clinic to prevent and treat T1D. Among them, induction of regulatory T cells (Treg) specific to β cell-associated autoantigens (BAA) for T1D therapy provides several advantages, including specificity and lasting effica- cy in controlling unrestricted autoimmunity. In this review, we discuss the progression of applying autoantigen-specific Treg cells in treating T1D, hoping to provide some useful information for future clinicians to develop more effective and safe antigen- specific immunoregulatory therapies on T1D treatment.


Autoantigen, β Cell, immunoregulatory therapies, organ-specific autoimmune disease, T regulatory cells, type I diabetes.


Department of Immunology, Cleveland Clinic Lerner Research Institute, Cleveland, Ohio 44195, USA., Department of Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, Louisiana 70803, USA.

Graphical Abstract:

Read Full-Text article